Updated on 2024/02/01

写真a

 
Tosa Mamiko
 
Affiliation
Nippon Medical School Hospital, Department of Plastic, Reconstructive and Aesthetic Surgery, Specially Appointed Professor
Title
Specially Appointed Professor
External link

Research Interests

  • scar management

  • keloid

  • postoperative scar

  • hypertrophic scar

  • wound healing

Research Areas

  • Life Science / Plastic and reconstructive surgery  / keloid

Research History

Papers

  • The Latest Strategy for Keloid and Hypertrophic Scar Prevention an Treatment: The Nippon Medical School (NMS) Protocol

    Rei Ogawa, Teruyuki Dohi, Mamiko Tosa, Masayo Aoki, Satoshi Akaishi

    JOURNAL OF NIPPON MEDICAL SCHOOL   88 ( 1 )   2 - 9   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MEDICAL ASSOC NIPPON MEDICAL SCH  

    In 2006, we established a scar/keloid-specialized unit in the Department of Plastic, Reconstructive, and Aesthetic Surgery at Nippon Medical School (NMS) in Tokyo, Japan. In the ensuing 15 years, we treated approximately 2,000 new scar/keloid patients annually. This extensive experience has greatly improved the efficacy of the treatments we offer. Therefore, we discuss here the latest NMS protocol for preventing and treating keloids and hypertrophic scars. While this protocol was optimized for Japanese patients, our experience with a growing body of non-Japanese patients suggests that it is also effective in other ethnicities. The extensive evidence-based experience underlying the NMS protocol suggests that it may be suitable as the foundation of a standard international prevention/treatment algorithm for pathological scars.

    DOI: 10.1272/jnms.JNMS.2021_88-106

    Web of Science

    PubMed

    researchmap

  • Combination Therapy Composed of Surgery, Postoperative Radiotherapy, and Wound Self-management for Umbilical Keloids. International journal

    Teruyuki Dohi, Shigehiko Kuribayashi, Masayo Aoki, Mamiko Tosa, Satoshi Akaishi, Rei Ogawa

    Plastic and reconstructive surgery. Global open   8 ( 10 )   e3181   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: A universally accepted therapeutic strategy for umbilical keloids has not been determined. Our team has had considerable success with combination therapy composed of surgical excision followed by postoperative radiotherapy and steroid plaster/injection. Methods: All consecutive patients with umbilical keloids that developed from endoscopic surgical scars and underwent minimal-margin keloid excision followed by umbilicoplasty with a flap if needed, tension-reduction suturing, and postoperative radiotherapy in 2013-2017 in the keloid/scar-specialized clinic at the Department of Plastic, Reconstructive and Aesthetic Surgery of Nippon Medical School. The postsurgical radiotherapy regimen was 15 Gy administered in 2 fractions over 2 consecutive days. Radiotherapy was followed by tension-reducing wound self-management with silicone tape or, if needed, steroid plaster. The primary study focus was keloid recurrence during the 24-month follow-up period. Recurrence was defined as the growth of stiff red lesions in even small areas of the scar that was refractory to 2-6 months of steroid-plaster therapy. Results: The case series consisted of 34 patients with 34 lesions. Three lesions (8.8%) recurred. One recurrence was successfully treated by concomitant steroid plaster/injection. The other 2 cases were resistant to steroid injection and underwent reoperation without radiotherapy followed by 6 months of steroid-plaster therapy. None of the 3 cases recurred within 2 years of steroid plaster/injection completion or reoperation. Conclusion: Umbilical keloids can be successfully treated by customized treatment plans that involve appropriate surgical modalities (including umbilicoplasty, if required), postoperative radiotherapy (15 Gy/2 fractions/2 days), and wound/scar self-management with silicone tape and steroid plaster.

    DOI: 10.1097/GOX.0000000000003181

    PubMed

    researchmap

  • Z-plasty and Postoperative Radiotherapy for Upper-arm Keloids: An Analysis of 38 Patients. Reviewed International journal

    Teruyuki Dohi, Shigehiko Kuribayashi, Mamiko Tosa, Masayo Aoki, Satoshi Akaishi, Rei Ogawa

    Plastic and reconstructive surgery. Global open   7 ( 11 )   e2496   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Therapies for upper arm keloids include surgical excision followed by postoperative radiotherapy, silicone tape stabilization, and steroid plaster. However, a universally accepted therapeutic strategy for upper-arm keloids is lacking. Methods: All consecutive patients with single upper-arm keloids who underwent keloid excision followed by tension-reducing suturing, multiple z-plasties, and postoperative radiotherapy in 2013-2016 in the keloid/scar specialist clinic at the Department of Plastic, Reconstructive and Aesthetic Surgery of Nippon Medical School, were included in this case series study. Only keloids that arose from the small injury produced during Bacillus Calmette-Guérin vaccination were selected. The postsurgical radiotherapy regimen was 18 Gy administered in 3 fractions over 3 days. Radiotherapy was followed by tension-reducing wound self-management with silicone tape and, if needed, steroid plaster. The primary study objective was keloid recurrence during the 24-month follow-up period. Recurrence was defined as the growth of stiff red lesions in even small areas of the scar that was refractory to at least 2 months of steroid plaster therapy. Results: In total, 38 patients with 38 lesions were enrolled. Two lesions (5.3%) recurred. Both recurrences were successfully treated by concomitant steroid plaster and steroid injection. The recurrence patients were significantly more likely than the nonrecurrence patients to have multiple keloids. The 2 groups did not differ in terms of original keloid size. Conclusions: Upper-arm keloids can be successfully treated by customized plans that involve appropriate surgical modalities (including multiple z-plasties), postoperative radiotherapy (18 Gy/3 fractions/3 d), and postoperative wound/scar self-management with silicone tape and steroid plaster.

    DOI: 10.1097/GOX.0000000000002496

    PubMed

    researchmap

  • 「手術の傷あとはどのまで治せるのか?」現状と今後の展望 Reviewed

    土佐眞美子

    瘢痕・ケロイド治療ジャーナル   13   17 - 20   2019

     More details

  • Two cases of granular cell tumor that clinically mimicked hypertrophic scars and keloids. Reviewed

    Tosa M, Ansai S, Kuwahara H, Akaishi S, Ogawa

    J Nippon Medical School   2018

     More details

  • Examination of Epithelial Mesenchymal Transition in Keloid Tissues and Possibility of Keloid Therapy Target. International journal

    Hiroaki Kuwahara, Mamiko Tosa, Seiko Egawa, Masahiro Murakami, Ghazizadeh Mohammad, Rei Ogawa

    Plastic and reconstructive surgery. Global open   4 ( 11 )   e1138   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Keloid is a fibroproliferative skin disorder that is characterized by collagen accumulation and blood vessel proliferation in the reticular layer of the dermis. It is caused by prolonged inflammation after cutaneous injury. Several studies suggested recently that epithelial mesenchymal transition (EMT) is involved in the development of fibrosis. This study assessed whether EMT also participates in keloid development and/or aggravation. METHODS: Resected keloid (n = 19) and normal skin (n = 13) samples were subjected to immunohistochemical, immunofluorescent, and Western blot analyses of their expression of epidermal (E-cadherin) and mesenchymal (vimentin) proteins. RESULTS: Immunohistochemical analysis showed that the keloid tissues had more vimentin-positive cells in the epidermis than the normal tissues. When normal primary keratinocytes were cultured with proinflammatory cytokines, the cobblestone-shaped cells changed to a spindle shape and many vimentin-positive cells were detected. When immortalized HaCaT keratinocytes were cocultured in split-well plates with normal or keloid-derived fibroblasts, they also underwent EMT, as indicated by their greater vimentin expression on Western blot analysis compared with HaCaT cells that were cultured alone. CONCLUSIONS: EMT was observed in keloid specimens. EMT was induced by inflammatory cytokines and fibroblasts. EMT may be involved in keloid generation and/or aggravation and may have potential as a keloid treatment target.

    PubMed

    researchmap

  • IL-6 Polymorphism and Susceptibility to Keloid Formation in a Japanese Population. Reviewed

    Mamiko Tosa

    J Invest Dermatol.   136 ( 11 )   e1138   2016

     More details

  • Refractory Leg Ulcers Associated with Klinefelter Syndrome Reviewed

    Yuto Yabuno, Mamiko Tosa, Itaru Iwakiri, Shunichi Nomoto, Mayuko Kaneko, Kousuke Kuwahara, Hiko Hyakusoku, Masahiro Murakami

    JOURNAL OF NIPPON MEDICAL SCHOOL   82 ( 1 )   67 - 70   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MEDICAL ASSOC NIPPON MEDICAL SCH  

    We present a man with refractory leg ulcers, bilateral varicosis of the lower extremities, and Buerger disease. Autoimmune work-up was negative. However, chromosome analysis showed Klinefelter syndrome (48 XXY). Ulcerative lesions of the lower extremities are a complication of Klinefelter syndrome. To date, the pathogenesis of ulcers in Klinefelter syndrome has not been clarified, but several factors, such as abnormalities of fibrinolysis and prothrombotic states, might be involved. Our present case emphasizes the importance of considering Klinefelter syndrome in the differential diagnosis of a male patient with nonhealing ulcers of the lower extremities.

    Web of Science

    researchmap

  • Identification and characterization of Wnt signaling pathway in keloid pathogenesis Reviewed

    Shinichi Igota, Mamiko Tosa, Masahiro Murakami, Seiko Egawa, Hajime Shimizu, Hiko Hyakusoku, Mohammad Ghazizadeh

    International Journal of Medical Sciences   10 ( 4 )   344 - 354   2013.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Keloid is characterized by fibroblastic cell proliferation and abundant collagen synthesis. Numerous studies have shown that the Wingless type (Wnt) signaling pathways play key roles in various cellular functions including proliferation, differentiation, survival, apoptosis and migration. The aim of this study was to clarify the role of Wnt signaling pathway in keloid pathogenesis. Primary fibroblast cultures and tissue samples from keloid and normal appearing dermis were used. The expression of Wnt family members, frizzled (FZD)4 receptor, receptor tyrosine kinase-like orphan receptor (ROR)2 and the Wnt signaling downstream targets, glycogen synthase kinase (GSK)3-β and β-catenin were assessed using semi-quantitative RT-PCR, Western blot, or immunohistochemical methods. Of the Wnt family members, Wnt5a mRNA and protein levels were elevated in keloid fibroblasts (KF) as compared to normal fibroblasts (NF). A higher expression of β-catenin protein was also found in KF. No detectable levels of FZD4 receptor and ROR2 proteins were observed in both NF and KF. Functional analysis showed that treatment of NF and KF with recombinant Wnt5a peptide resulted in an increase in protein levels of total β-catenin and phosphorylated β-catenin at Ser33/37/Thr 41 but no significant change in phosphorylated β-catenin at Ser45/Thr 41 positions. In addition, the expression of total GSK3-β protein was not affected but its phosphorylated/inactivated form was increased in NF and KF. Our findings highlight a potential role for a Wnt/β-catenin canonical signaling pathway triggered by Wnt5a in keloid pathogenesis thereby providing a new molecular target for therapeutic modulations. © Ivyspring International Publisher.

    DOI: 10.7150/ijms.5349

    Scopus

    PubMed

    researchmap

  • 手術後瘢痕と産婦人科 産婦人科手術後肥厚性瘢痕・ケロイド発生予防を目的とした手術後早期瘢痕ケア外来の実際とその成果について Reviewed

    土佐眞美子

    産婦人科の実際   62 ( 13 )   2175 - 2180   2013

     More details

    Language:Japanese   Publisher:金原出版  

    CiNii Books

    researchmap

    Other Link: http://search.jamas.or.jp/link/ui/2014106786

  • Analysis of distribution of helper T cells in keloid patient Reviewed

    Mamiko Tosa

    Cytometry Redearch   23   69   2013

     More details

  • Chronologic Change of the Maximum Dimension of Bacillus Calmette-Guerin-Induced Keloids Reviewed

    Mamiko Tosa, Masahiro Murakami, Mohammad Ghazizadeh, Hiko Hyakusoku

    DERMATOLOGIC SURGERY   35 ( 2 )   189 - 194   2009.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL PUBLISHING, INC  

    Because keloids grow gradually, there is a long time lag until the patients visit the hospital.
    To investigate the chronologic change of the maximum dimension of Bacillus Calmette-Guerin (BCG)-induced keloids to provide information on their nature and facilitate early treatment intervention.
    Clinical records of patients with keloid treated between 1998 and 2005 were reviewed, and patients with BCG-induced keloids were assessed with reference to age at onset of keloid, age at first hospital visit, length of the major axis of keloid at first visit, growth rate, and histopathologic features.
    Of 716 patients with keloid, 60 (8.4%) had BCG-induced keloid. A significant difference was found between mean age at onset and at first visit. The mean length of maximum dimension was 42.4 mm and increased proportionally to age at first visit. Keloids grew rapidly between the ages of 20 and 40, during which time many patients did not seek therapy. Histopathologically, no significant differences were noted between BCG-induced keloid and non-BCG keloid.
    Early therapeutic intervention might prevent keloids from growing larger, emphasizing a need to provide adequate information on keloid behavior to patients and physicians involved in BCG vaccination.
    The authors have indicated no significant interest with commercial supporters.

    DOI: 10.1111/j.1524-4725.2008.34408.x

    Web of Science

    researchmap

  • Effect of lidocaine tape on pain during intralesional injection of triamcinolone acetonide for the treatment of keloid. Reviewed

    Mamiko Tosa

    J Nihon Med Sch.   76 ( 1 )   9 - 12   2009

     More details

  • Global gene expression analysis of keloid fibroblasts in response to electron beam irradiation reveals the involvement of interleukin-6 pathway. Reviewed

    Mamiko Tosa

    J Invest Dermatol. Nippon Medical School   127 ( 1 )   98 - 105   2007

     More details

▼display all

Misc.

  • 傷あとを目立たなくするための切開・縫合法と術後ケアの最適化

    小川 令, 赤石 諭史, 土肥 輝之, 土佐 眞美子

    瘢痕・ケロイド治療ジャーナル   ( 14 )   21 - 24   2020.9

     More details

    Language:Japanese   Publisher:(株)全日本病院出版会  

    researchmap

  • ケロイドの手術的治療 ケロイドの手術法の実際 皮膚への力学的刺激の最小化に向けて

    土肥 輝之, 土佐 眞美子, 青木 雅代, 小川 令, 赤石 諭史

    日本形成外科学会会誌   40 ( 8 )   422 - 422   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本形成外科学会  

    researchmap

  • 当院における耳ケロイドの治療戦略

    加来 知恵美, 赤石 諭史, 土肥 輝之, 土佐 眞美子, 小川 令

    形成外科   63 ( 5 )   630 - 639   2020.5

     More details

    Language:Japanese   Publisher:克誠堂出版(株)  

    当院では耳ケロイドに対し基本的に外科的切除+術後放射線治療の組み合わせを第一選択としており、外来受診、手術、放射線治療(1〜2日)、抜糸の最低4〜5日間の通院で治療が可能である。外科的切除では耳垂には楔状切除、耳介にはくり抜き法を基本とし、症例に応じてZ形成術や皮弁作成術を追加しており、術後はケロイドの再発予防を目的として十分な圧迫固定を行い、基本的には術後3日以内に放射線治療を開始している。また、術後は1〜1ヵ月半毎に6ヵ月〜数年間の経過観察を行い、術後創部の硬さを認める症例には早期よりステロイド治療を開始している。現時点で再発率の上昇はなく、放射線治療に伴う有害事象も認めていない。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2020&ichushi_jid=J00398&link_issn=&doc_id=20200526120014&doc_link_id=%2Fad3ksgke%2F2020%2F006305%2F021%2F0630-0639%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fad3ksgke%2F2020%2F006305%2F021%2F0630-0639%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 下顎ケロイドに対する手術,術後放射線治療および副腎皮質ステロイドテープ剤を用いた集学的治療

    井上真梨子, 土肥輝之, 土佐眞美子, 青木雅代, 小川令, 赤石諭史

    日本医科大学医学会雑誌   16 ( 4 )   273 - 273   2020

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    J-GLOBAL

    researchmap

  • ケロイド・肥厚性瘢痕治療の最新アルゴリズム

    小川令, 土肥輝之, 土佐眞美子, 赤石諭史

    日本医科大学医学会雑誌   16 ( 4 )   274 - 274   2020

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    J-GLOBAL

    researchmap

  • ケロイド真皮網状層エオジン好性エリアの電顕観察:筋線維芽細胞とkeloidal collagen

    加来知恵美, 市野瀬志津子, 土肥輝之, 松本典子, 野一色千景, 有馬樹里, 青木雅代, 赤石諭史, 土佐真美子, 小川令

    日本医科大学医学会雑誌   15 ( 4 )   252 - 252   2019

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    J-GLOBAL

    researchmap

  • BCGワクチン接種による上腕ケロイドに対する全切除・Z形成術および術後放射線治療の治療結果の検討

    土肥輝之, 土佐眞美子, 青木雅代, 赤石諭史, 小川令

    日本医科大学医学会雑誌   15 ( 4 )   253 - 254   2019

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    J-GLOBAL

    researchmap

  • 瘢痕、ケロイド治療のstate-of-the-art ケロイド・肥厚性瘢痕は完治できる!

    小川 令, 土佐 眞美子, 土肥 輝之, 青木 雅代, 赤石 諭史

    日本創傷治癒学会プログラム・抄録集   48回   87 - 87   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本創傷治癒学会  

    researchmap

  • ケロイド・肥厚性瘢痕の病態とその診断と治療

    小川令, 土佐眞美子, 土肥輝之, 青木雅代, 杉本貴子, 松本典子, 野一色千景, 加来知恵美, 市野瀬志津子, 赤石諭史

    日本医科大学医学会雑誌   14 ( 4 )   210 - 210   2018

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    J-GLOBAL

    researchmap

  • Congenital auricular fistula involving the lobule with caudal extension of an abscess

    Kosuke Kuwahara, Masahiro Murakami, Hiko Hyakusoku, Mamiko Tosa

    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY   67 ( 12 )   1749 - 1750   2014.12

     More details

    Language:English   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:ELSEVIER SCI LTD  

    DOI: 10.1016/j.bjps.2014.07.025

    Web of Science

    researchmap

  • Clinical Improvement in Psoriasis With Treatment of Associated Hyperlipidemia

    Ramin Ghazizadeh, Mamiko Tosa, Mohammad Ghazizadeh

    AMERICAN JOURNAL OF THE MEDICAL SCIENCES   341 ( 5 )   394 - 398   2011.5

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Psoriasis is associated with an increased risk of cardiovascular disease, a principal cause of which is atherosclerosis caused by hyperlipidemia. However, it is not known whether treatment of hyperlipidemia in patients with psoriasis lead to clinical improvement in psoriasis condition. In this study, the authors summarize the existing literature relevant to this inquiry. They also describe the potential pathways believed to link psoriasis with atherosclerosis and the role of hyperlipidemia therapy in this setting. A few studies indicated clinical improvement in psoriasis with treatment of associated hyperlipidemia. Some studies showed that a low-fat diet improved psoriasis. Others indicated a decreased risk of psoriasis associated with intake of cholesterol-lowering drugs such as "statins." Treatment with statins increased lactate dehydrogenase level and diminished Psoriasis Area and Severity Index score, ie, reduced cutaneous lesion in psoriasis. Beneficial effects of statin therapy on psoriasis included downregulation of lymphocyte function-associated antigen-1, inhibition of leukocyte endothelial adhesion, extravasation and natural killer cell activity, inhibition of proinflammatory cytokines such as tumor necrosis factoralpha and interleukin 1 and 6, lowering of C-reactive protein, promotion of a T(H)1 to T(H)2 cells and inhibition of T(H)1 cytokine receptors on T cells, leading to inhibition of activation of lymphocytes and infiltration into the inflammation sites. Taken together, current literature indicates clinical improvement in psoriasis condition with treatment of associated hyperlipidemia, particularly with statins of which the mechanisms could be attributed to immunomodulatory and anti-inflammatory effects.

    DOI: 10.1097/MAJ.0b013e3181ff8eeb

    Web of Science

    researchmap

▼display all

Research Projects

  • 空間的な遺伝子解析によるケロイド発生機序の解明と新規治療標的の導出

    Grant number:23K09106  2023.4 - 2026.3

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    土佐 眞美子

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    researchmap

  • PRMT5による新たなケロイド幹細胞制御機構の解明と新治療薬開発への挑戦

    Grant number:20K09855  2020.4 - 2023.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    土佐 眞美子, 阿部 芳憲

      More details

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    ケロイドは、ヒト特有の疾患であるために原因解明には至っていない。、そのため、特効薬の開発は困難で、臨床現場では、対処療法がメインとなっているのが現状である。今までのケロイド研究は、ケロイド由来の線維芽細胞を用いたものががほとんどであった。われわれは、ケロイド組織例の約10%に異所性骨化を認めることを見出し、正常皮膚には存在しないはずの細胞がケロイド内に存在するのではないかと考えた、その起源として、組織異常幹細胞(ケロイド真皮幹細胞)に着目した。これまでに、得られた予備知見として、ケロイド患者では、ケロイド真皮 由来幹細胞におけるPRMT5発現が亢進しており、それは、第一世代のPRMT5阻害薬により、抑制されたことがあげられる。ケロイド真皮由来幹細胞やケロイド組織 におけるPRMT5タンパク発現の亢進のとケロイド組織を用いてPRMT5の免疫組織学的染色を行い、その発現分布を確認して、それぞれ、正常皮膚との比較を行った。 現在、ケロイド真皮由来幹細胞においてPRMT5がどのような遺伝子群を制御しているのかを明らかにするために、KSにiRNAを安定発現させてPRMT5発現を抑制後、細胞から、RNAを抽出して、多角的に発現解析を行い、PRMT5が発現制御する遺伝子群の役割をpathway解析ソフトを用いて、発現2倍以上でp値の低い順にPRMT5標的遺伝子を絞り込み、その結果の検証作業に入っている。

    researchmap

  • 新たなケロイド治療法開発を目指した新規ケロイド幹細胞維持機構の解明

    2017.4 - 2020.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Elucidation of immune response by Th17/Treg in keloid and application of new therapy

    Grant number:26462738  2014.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    MURAKAMI MASAHIRO, MINAMI SHIROU

      More details

    Grant amount:\4940000 ( Direct Cost: \3800000 、 Indirect Cost:\1140000 )

    We studied the Th17/Treg balance in a peripheral blood and keloid tissues. There was significant difference of Th17/Treg balance in the keloid tissues compared with control. High expression of IL17 and IL10 was found in keloid tissues compared to normal skin. Treatment of normal fibroblast with recombinant IL17 and IL10 peptide resulted in an increase in collagen synthesis. These finding highlight a potential role for Th17/Treg balance triggered by IL10 and IL17 in keloid pathogenesis and development of molecular therapy for keloid.

    researchmap

  • ケロイド発生に関するIL-6プロモーター領域一塩基多型の同定とその機能解析

    2012.4 - 2015.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Elucidation of Wnt5a signal transduction mechanism(s) in keloid and application of molecular targeted therapy

    Grant number:24592722  2012.4 - 2015.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    GHAZIZADEH MOHAMMAD, TOSA Mamiko, SHIMIZU Hajime, MURAKAMI Masahiro

      More details

    Grant amount:\4940000 ( Direct Cost: \3800000 、 Indirect Cost:\1140000 )

    We studied the expression and function of Wnt5a considering frizzled4 receptor, ROR2, Wnt signal downstream targets (GSK3-beta and beta-catenin) as well as epithelial-mesenchymal transition (EMT) markers and 84 Wnt signal-related genes in primary fibroblast cultures and tissue samples from keloid (KF) and normal dermis (NF)using molecular biology, immunohistochemical and RT2 Profiler PCR Array methods. A high expression of Wnt5a and beta-catenin was found in KF compared to NF. Treatment of NF and KF with recombinant Wnt5a peptide resulted in an increase in total beta-catenin and phosphorylated beta-catenin at Ser33/37/Thr41 but no significant change in phosphorylated beta-catenin at Ser45/Thr41 positions. Several Wnt signal-related genes were also upregulated. In addition, evidence for EMT in keloid was observed. These findings highlight a potential role for a Wnt/beta-catenin pathway triggered by Wnt5a in keloid pathogenisis and development of molecular targeted therapy for keloid.

    researchmap

  • The mechanisms of transcriptional regulation by microRMAs in relation to COLIA2 promotor region in keloid

    Grant number:22592003  2010 - 2012

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    SHIMIZU Hajime, M Ghazizadeh, TOSA Mamiko

      More details

    Grant amount:\3380000 ( Direct Cost: \2600000 、 Indirect Cost:\780000 )

    We aimed to investigate expression profiles of microRNAs (miRNAs) in order to understanding the molecular mechanism(s) involved in the pathogenesis of keloid. We confirmed that miR-10a was significantly under-expressed in keloid fibroblasts (KFs) compared with normal dermal fibroblasts (NFs).Inhibition and induction of miR-10a respectively by miRNA inhibitor and retinoic acid (RA) in KFs and NFs revealed that IL-6 and pro-collagen type I (PICP) secretions in the culture supernatants were decreased by miR-10a inhibitor and increased by RA treatment. These results suggest that miR-10a regulates the synthesis and secretion of collagen in KFs and NFs. KF and NF cells were transfected with miR-10a oligonucleotide. The secretion of PICP was reduced in miR-10a transfected KFs and NFs. The miR-10a was significantly over-expressed in KFs and NFs after treatment with RA. The treated cells were harvested for miR-10a qPCR assay and the culture supernatant was analyzed for IL-6 and PICP secretion by ELISA method. The assays indicated that IL-6 concentrations were markedly increased in KFs compared with NFs after RA treatment.Our data confirmed the differential expression of miR-10a in KFs compared with NFs. The miR-10a regulates the synthesis and secretion of collagen in KFs and NFs. Down-regulation of miR-10a may be one of the mechanisms by which collagen is highly deposited in KFs. Our results showed that miR-10a is a promising new effective strategy for targeting keloid lesions.

    researchmap

  • ケロイド発生に関するIL-23/IL17免疫経路の役割解明と新治療の確立

    2009.4 - 2012.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Establishment of new molecular therapy of keloid and elucidation of mechanism of development by inhibition of cAbl tyrosine kinase

    Grant number:21592297  2009 - 2011

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    GHAZIZADEH M., TOSA Mamiko, SHIMIZU Hajime, MURAKAMI Masahiro

      More details

    Grant amount:\3640000 ( Direct Cost: \2800000 、 Indirect Cost:\840000 )

    We have shown that IL-6 signaling pathway is involved in keloid development. The present study aimed at analysis of the inhibitory effect of small molecule therapeutic agent STI571(imatinib mesylate) and small molecule peptide PD173955 which simultaneously inhibit TGF-β receptor and PDGF receptor and c-Abl tyrosine kinase signaling on keloid. Over-expression of c-Abl, TGF-β receptor, PDGF receptor was found in keloid-derived fiboblasts(KF). Treatment of both normal dermal fibroblasts(NF) and KF cells with STI571 and PD173955 resulted in inhibitory effect on cell growth, migration, ECM-related gene expression, and apoptosis. In addition, inhibition of STI571 and PD173955 abolished the effect on cell growth, collagen synthesis and apoptosis. Implantation of keloid and normal skin tissues into nude mice showed hardening of subcutaneous tissue after 5 weeks which on histological examination revealed accumulation of collagen bundles. Subsequently, we treat these mice with STI571 and PD173955 and evaluate their effects. These results indicate that inhibition of c-Abl tyrosine kinase may prove useful for the development of new molecular therapy of keloid.

    researchmap

  • IL-6シグナル制御によるケロイドの新しい分子治療の確立と発症機序の解明

    2006.4 - 2009.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • ケロイド発生におけるWntシグナル分子機構の解明と新しい分子標的治療に関する研究

    2003.4 - 2006.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Identification of genes associated with keloid development

    Grant number:13671886  2001 - 2002

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    GHAZIZADEH Mohammad, KAWAKNAMI Oichi, TOSA Mamiko, HIRAI Takashi, EMI Mitsuro

      More details

    Grant amount:\2000000 ( Direct Cost: \2000000 )

    Keloid formation results from abnormal wound healing, however the molecular mechanisms regulating this process remain undetermined. With the advent of cDNA microarray technology, variations in cellular transcriptional events can be monitored simultaneously, and expression profile of each state can be established and compared to its counterpart state. We performed gene expression profile analysis of fibroblasts from healthy skin and keloid tissues after obtaining informed consents. Fibroblast cultures were established by outgrowth from healthy skin and keloid tissue samples obtained at surgery. After two subculturing, monolayer cells at 80-90% confluency were lysed, total RNA was extracted and ^<33>P-labeled cDNA probe was prepared. The probes were hybridized to Derm Array GeneFilters and the scanned filter images were analyzed and compared using the Pathways software. Several genes related to the cell cycling, apoptotsis, extracellular matrix formation/degradation, growth factors, protease inhibitors, and focal adhesions were identified. Among these, c-Abl (a tyrosine kinase) and cdc25A (a tyrosine phosphatase) were noteworthy because of their important roles in signal transduction pathways. We intend to further pinpoint the roles of these genes in the development of keloid using RNA interference (RNAi) method. Hitherto, our results suggest a "synthetic" fibroblast phenotype in keloid lesion chracterized by an accelerated cell cycle combined with induction of matrix synthesis and inhibition of matrix degradation. Identification of these genes that are involved in keloid formation may help better understand its molecular and cellular biology.

    researchmap

  • 新しい樹脂鋳型標本を用いた真皮下血管網皮弁における3次元的血管新生の研究

    1999.4 - 2001.3

    文科省  科学研究費 

    土佐眞美子

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

▼display all